RESEARCH USE AND EDUCATIONAL DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
Vasoactive intestinal peptide, or VIP, has been studied in vascular signaling and pulmonary biology. Aviptadil is a synthetic form investigated in clinical trials. The research includes an early pulmonary-hypertension study and randomized trials in severe COVID-19 respiratory failure. Encouraging early observations did not translate into a demonstrated benefit in the larger TESICO comparison. This review explains the progression of the evidence and why primary outcomes deserve more weight than selected secondary findings. [1–3]
WHAT VIP RESEARCH IS ABOUT
VIP is a signaling peptide with effects on blood vessels and other biological systems. Its ability to influence pulmonary vascular activity helped motivate clinical investigation. Aviptadil studies concern a defined investigational preparation of synthetic VIP, rather than every material carrying the VIP name. [1–3]
A biological effect creates a hypothesis. To establish a clinical benefit, researchers must test whether that effect improves meaningful outcomes in an appropriate controlled study. A mechanism alone cannot answer that question.
THE EARLY PULMONARY-HYPERTENSION STUDY
Petkov and colleagues published a 2003 investigation of VIP in primary pulmonary hypertension. The paper combined biological research with observations in eight patients. Investigators reported lower mean pulmonary arterial pressure and increases in cardiac output and mixed venous oxygen saturation after the studied intervention. [1]
Those findings provided an early signal in a serious pulmonary vascular condition. The small clinical series was not a large randomized placebo-controlled efficacy trial. It could not establish broad effectiveness, durability or the full range of possible adverse effects. [1]
Pulmonary hypertension and acute respiratory failure from an infection are also different conditions. A favorable observation in one cannot be assumed to predict the result in the other.
THE FIRST COVID-19 RANDOMIZED REPORT
Youssef and colleagues reported a 2022 multicenter trial involving 196 patients with critical COVID-19 respiratory failure. Participants were randomized to aviptadil or placebo. The prespecified primary endpoint combined survival with freedom from respiratory failure at day 60. [2]
That primary endpoint did not show a statistically significant difference. The reported odds ratio was 1.6, with a confidence interval from 0.86 to 3.11. A separate survival analysis and some subgroup findings favored aviptadil, and the authors discussed these as encouraging signals. [2]
These results should be reported together. Describing the paper only as a survival success would omit its negative primary result. Secondary and subgroup analyses can motivate further research, but they require care because multiple analyses create more opportunities for apparently positive findings.
WHAT THE LARGER TESICO TRIAL FOUND
Brown and colleagues reported the TESICO study in 2023. It enrolled patients at 28 United States sites with COVID-19-associated acute hypoxemic respiratory failure. For the aviptadil comparison, 471 participants were randomized and 461 who received at least part of the assigned infusion were included in the modified intention-to-treat population. [3]
Aviptadil did not significantly improve the primary day-90 outcome ranking. The odds ratio for a better outcome category was 1.11, with a 95% confidence interval from 0.80 to 1.55. Mortality through day 90 was approximately 38% with aviptadil and 36% with placebo; this did not demonstrate a survival benefit. [3]
The trial also included a remdesivir comparison, but that should not be read as a single test of an aviptadil–remdesivir combination. The study design allowed evaluation of the separate agents. [3]
HOW TO INTERPRET MIXED RESULTS
An early positive signal and a later negative trial can coexist. Studies differ in participant selection, background care, sample size and outcome definitions. The appropriate response is to examine those differences and give substantial weight to the larger controlled result, rather than choosing whichever finding supports a preferred conclusion.
Likewise, failure to demonstrate a benefit in severe COVID-19 does not prove VIP has no biological activity or could never be useful in another setting. It does mean that a broad claim of established respiratory benefit is not supported by these trials.
THE RESEARCH-USE BOUNDARY
The cited studies do not establish universal safety, justify personal experimentation or validate a separate commercial research batch. They concern specific interventions under clinical oversight, and early observations cannot replace systematic safety evaluation.
For qualified research, the useful focus is the exact molecular preparation, disease model and prespecified outcome. This article provides an educational account of published evidence without recommending VIP for personal use or supplying administration instructions.
REFERENCES
1. Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. Journal of Clinical Investigation. 2003;111:1339–1346.
https://doi.org/10.1172/JCI17500
2. Youssef JG, Lavin P, Schoenfeld DA, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Critical Care Medicine. 2022;50:1545–1554.
https://doi.org/10.1097/CCM.0000000000005660
3. Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respiratory Medicine. 2023.
https://doi.org/10.1016/S2213-2600(23)00147-9